Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody–drug conjugate mirvetuximab soravtansine

Clinical Cancer Research

Volumn 25, Issue 6, 2019, Pages 1727-1736

  Matulonis, Ursula A ^a   Birrer, Michael J ^b,l   O'Malley, David M ^c   Moore, Kathleen N ^d   Konner, Jason ^e   Gilbert, Lucy ^f   Martin, Lainie P ^g   Bauer, Todd M ^h   Oza, Amit M ⁱ   Malek, Karim ^j   Pinkas, Jan ^j   Kim, Stella K ^k  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g FOX CHASE CANCER CENTER   (United States)

^h SARAH CANNON RESEARCH INSTITUTE   (United States)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j IMMUNOGEN INC   (United States)

^k UNIVERSITY OF TEXAS   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; FOLATE RECEPTOR 1; MIRVETUXIMAB SORAVTANSINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TAXANE DERIVATIVE; ANTIBODY CONJUGATE; EYE DROPS; FOLR1 PROTEIN, HUMAN; GLUCOCORTICOID; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; ADVERSE DRUG REACTION; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORNEA DISEASE; CORNEA TISSUE; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; EYE TOXICITY; FATIGUE; HUMAN; HUMAN TISSUE; KERATOPATHY; MALE; MONOTHERAPY; MOUSE; NAUSEA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CLINICAL TRIAL; CORNEA; DRUG ADMINISTRATION; DRUG EFFECT; DRUG RESISTANCE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LEPORIDAE; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PRECLINICAL STUDY; TOXICITY TESTING; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CORNEA; CORNEAL DISEASES; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLATE RECEPTOR 1; GLUCOCORTICOIDS; HUMANS; IMMUNOCONJUGATES; INFUSIONS, INTRAVENOUS; MALE; MAYTANSINE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; OVARIAN NEOPLASMS; RABBITS; TOXICITY TESTS, SUBACUTE; TREATMENT OUTCOME;

EID: 85063014343     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-18-2474     Document Type: Article

References (31)

1. al-Tweigeri T, Nabholtz JM, Mackey JR. Ocular toxicity and cancer chemotherapy: a review. Cancer 1996;78:1359–73.
2. Singh P, Singh A. Ocular adverse effects of anti-cancer chemotherapy and targeted therapy. J Cancer Thera Res 2012;1:5.
3. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. J Clin Oncol 2012;30:3277–86.
4. Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, et al. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget 2017;8:58709–27.
5. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013;63:249–79.
6. Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 2014;53:3796–827.
7. Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 2017;16:315–37.
8. Parslow AC, Parakh S, Lee FT, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Biomedicines 2016;4:14
9. Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 2016;8:659–71.
10. Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 2015;31:589–604.
11. Gunderson CC, Moore KN. Mirvetuximab soravtansine: FRa-targeting ADC treatment of epithelial ovarian cancer. Drugs of the Future 2016;41: 539–45.
12. Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, et al. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol 2018;14:123–36.
13. Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors. Cancer 2017;123:3080–87.
14. Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol 2017;35:1112–18.
15. Wilson SL, Ahearne M, Hopkinson A. An overview of current techniques for ocular toxicity testing. Toxicology 2015;327:32–46.
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228–47.
17. Smith SB, Kekuda R, Gu X, Chancy C, Conway SJ, Ganapathy V. Expression of folate receptor alpha in the mammalian retinol pigmented epithelium and retina. Invest Ophthalmol Vis Sci 1999;40: 840–8.
18. Chancy CD, Kekuda R, Huang W, Prasad PD, Kuhnel JM, Sirotnak FM, et al. Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J Biol Chem 2000;275: 20676–84.
19. Janssen SF, Gorgels TG, Bossers K, Ten Brink JB, Essing AH, Nagtegaal M, et al. Gene expression and functional annotation of the human ciliary body epithelia. PLoS One 2012;7:e44973.
20. Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, et al. FORWARD I: a phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol 2018;14:1669–1678.
21. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immu-noconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012; 30:2776–82.
22. Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev 2016;68:3–19.
23. Rehman I, Ali T. Anatomy, head, eye, muscles, ciliary. In:StatPearls. Treasure Island, FL: StatPearls Publishing; 2018.
24. Coca-Prados M, Escribano J. New perspectives in aqueous humor secretion and in glaucoma: the ciliary body as a multifunctional neuroendocrine gland. Prog Retin Eye Res 2007;26:239–62.
25. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf 2008;31:127–41.
26. Zhao H, Atkinson J, Gulesserian S, Zeng Z, Nater J, Ou J, et al. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates. Cancer Res 2018;78:2115–26.
27. Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, et al. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro Oncol 2018;20:838–47.
28. Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, et al. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Cancer 2018;124:2174–83.
29. Fathi AT, Chen R, Trippett TM, O'Brien MM, De Angelo DJ, Shah BD, e t a l. I n te r i m a n a l y s i s o f a p h as e I s tu d y o f th e antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma. Blood 2014;124:963.
30. Moskowitz CH, Forero-Torres A, Shah BD, Advani R, Hamlin P, Kim S, et al. Interim analysis of a phase I study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage non-Hodgkin lymphoma. Blood 2014;124:1471.
31. Klein R, Klein BE. The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Invest Ophthalmol Vis Sci 2013;54:ORSF5–ORSF13.